Abstract Details

Title Comparison of Plasma Exchange, Methylprednisolone Pulse Therapy and Intravenous Immunoglobulin in Oxidative Stress

Topic MS and Related Diseases

Presentation(s) P01 - (-)

Poster/Presentation
Number 190

Objective

Background BACKGROUND: Oxidative stress refers to the cytopathologic consequences of a mismatch between the production of free radicals and the ability of the cell to defend against them. Excessive oxidative stress is thought to have an important role in the pathogenesis of autoimmune diseases by enhancing the inflammation and breaking down the immunological tolerance.

Design/Methods DESIGN/METHODS: In this report, as an oxidative stress marker we studied diacron reactive oxygen metabolites (d-ROMs) which relates to endothelial damage and biological antioxidant potential (BAP) was also studied from 26 (12 men and 14 women) patients with neuroimmunological diseases (10 myasthenia gravis, 6 neuromyelitis optica, 4 chronic inflammatory demyelinating polyneuropathy, 3 encephalitis, 2 Guillain-Barre syndrome, 1multiple sclerosis). Blood sample was collected from each patient before and after PE (23 immunoadsorption, 3 double filtration) and we examined d-ROMs and BAP. We checked the level of d-ROMs and BAP at other treatment (13 methylprednisolone pulse therapy, 10 intravenous immunoglobulin: IVIG) as a control.

Results RESULTS: The level of d-ROMs was markedly decreased after PE (p<0.001) and was also decreased after methylprednisolone pulse therapy (p<0.01) comparing to before the treatment but not after IVIG treatment. The level of BAP was decreased only after methylprednisolone pulse therapy (p<0.03). We have not found any correlation between the level of d-ROMs or BAP and the efficacy of each therapy.

Conclusions CONCLUSIONS: PE has a strong effect of scavenging oxidative stress. Methylprednisolone pulse therapy has some effect of scavenging oxidative stress but also has a potential of decreasing antioxidant effect. IVIG does not have any effect of decreasing oxidative stress or decreasing antioxidant effect.

Authors/Disclosures
PRESENTER	No disclosure on file
Hikoaki Fukaura, MD (Nemuro City Hospital)	No disclosure on file
Mark S. Freedman, MD, FAAN (University of Ottawa)	Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Actelion(Janssen/J&J). Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BiogenIdec. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS/Celgene. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Inc. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Actelion (Janssen/J&J). Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Atara Biotherapeutics. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer Healthcare. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for BiogenIdec. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Clene Nanomedicine. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GRI Bio. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Magenta Therapeutics. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Freedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Freedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. The institution of Dr. Freedman has received research support from Sanofi Genzyme.
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��